Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Sperimentazione per valutare la sicurezza e l'efficacia del supporto circolatorio meccanico in pazienti con insufficienza cardiaca avanzata (TEAM-HF)

3 novembre 2026 aggiornato da: Abbott Medical Devices

The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.

Panoramica dello studio

Descrizione dettagliata

Patients with heart failure (HF) suffer from a high degree of morbidity and mortality. Left ventricular assist device (LVAD) therapy has become the standard of care for the treatment of advanced HF patients who are deemed to be dependent on continuous intravenous inotropes, extending life expectancy, enhancing overall quality of life, and improving functional capacity. However, use of LVADs in ambulatory, non-inotrope dependent advanced HF population is limited. Elevated mean pulmonary artery pressure (PAP) secondary to left ventricular failure has emerged as a potential predictor of increased mortality risk for patients refractory to maximally tolerated guideline directed medical therapy (GDMT). In these patients, left ventricular failure with elevated mean PAP may represent objective criteria to identify advanced HF patients requiring heart replacement therapies such as LVAD.

The TEAM-HF IDE trial will enroll approximately 850 subjects with New York Heart Association (NYHA) Class IIIB/IV HF who had a prior heart failure hospitalization and an elevated mean PAP secondary to left ventricular failure. Elevated mean PAP will be identified using an implanted PAP monitoring sensor, the CardioMEMS PA Sensor. All subjects enrolled can have a previously implanted CardioMEMS PA Sensor or, if not, will be implanted with the CardioMEMS PA Sensor after enrollment. The overall objectives of TEAM-HF trial are two-fold: 1) To determine whether PAP can objectively identify patients most at risk for worsening HF and therefore most likely to benefit from earlier intervention with LVAD therapy and 2) To determine the benefit of LVAD therapy in non-inotrope advanced HF patients with elevated mean PAP refractory to GDMT.

The trial will include approximately 75 global sites and consists of a Randomized Arm and a Single Arm Registry.

The TEAM-HF Randomized Arm is a prospective, randomized, open-label study of the HeartMate 3 (HM3) left ventricular assist system (LVAS) versus continued GDMT in non-inotrope dependent HF patients. The objectives of the Randomized Arm are 1) To establish an objective disease-state criteria to trigger referral for a HM3 LVAS and 2) Demonstrate improvement in survival when non-inotrope dependent advanced HF patients are treated with the HM3 LVAS compared to being managed on medical therapy alone.

The TEAM-HF Single Arm Registry is a prospective, single-arm, open-label study of non-inotrope dependent HF patients who do not meet a mean PAP threshold after GDMT optimization. The objective of the Single Arm Registry is to characterize the progression of patients with non-inotrope dependent HF without elevated PAP.

Tipo di studio

Interventistico

Iscrizione (Stimato)

850

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Riyadh Region
      • Riyadh, Riyadh Region, Arabia Saudita, 11525
        • Reclutamento
        • King Fahad Medical City
        • Investigatore principale:
          • Mohammed Alreshidan, MD
        • Contatto:
      • Riyadh, Riyadh Region, Arabia Saudita, 12713
        • Reclutamento
        • King Faisal Specialist Hospital
        • Contatto:
        • Investigatore principale:
          • Jehad Abdulhamid Al Buraiki, MD
    • State of Vienna
      • Vienna, State of Vienna, Austria, 1090
        • Reclutamento
        • AKH -Wien
        • Contatto:
        • Investigatore principale:
          • Daniel Zimpfer, MD
    • CBohmia
      • Prague, CBohmia, Cechia, 14021
        • Reclutamento
        • IKEM Prague
        • Investigatore principale:
          • Ivan Netuka, MD
        • Contatto:
    • Copenhagen
      • Copenhagen, Copenhagen, Danimarca, 2100
        • Reclutamento
        • Rigshospitalet
        • Contatto:
        • Investigatore principale:
          • Kasper Rossing, MD
    • Saxon
      • Hanover, Saxon, Germania, 30625
        • Reclutamento
        • Medizinische Hochschule Hannover
        • Investigatore principale:
          • Dominik Berliner, MD
        • Contatto:
    • Saxony
      • Leipzig, Saxony, Germania, 04289
    • State of Berlin
      • Berlin, State of Berlin, Germania, 13353
        • Reclutamento
        • Deutsches Herzzentrum der Charité
        • Investigatore principale:
          • Felix Schoenrath, MD
        • Contatto:
    • Piedmont
      • Turin, Piedmont, Italia, 10126
        • Reclutamento
        • A.O.U. Citta della Salute e della Scienza di Torino
        • Contatto:
        • Investigatore principale:
          • Antonino Loforte, MD
    • Holland
      • Rotterdam, Holland, Olanda, 3015 CE
        • Reclutamento
        • Erasmus MC - Thoraxcenter
        • Contatto:
        • Investigatore principale:
          • Rudolf De Boer, MD
    • Utrecht
      • Utrecht, Utrecht, Olanda, 3584 CX
        • Reclutamento
        • UMC Utrecht
        • Investigatore principale:
          • Linda Van Laake, MD
        • Contatto:
    • Arizona
      • Phoenix, Arizona, Stati Uniti, 85006
        • Ritirato
        • Banner-University Medical Center Phoenix
    • Arkansas
      • Little Rock, Arkansas, Stati Uniti, 72205
        • Reclutamento
        • Baptist Health Medical Center
        • Investigatore principale:
          • Patrick Campbell, MD
        • Contatto:
    • California
      • Sacramento, California, Stati Uniti, 95816
        • Reclutamento
        • Sutter Medical Center
        • Contatto:
        • Investigatore principale:
          • Michael Gibson, MD
      • San Francisco, California, Stati Uniti, 94143
        • Reclutamento
        • University of California at San Francisco
        • Contatto:
        • Investigatore principale:
          • Shweta Motiwala, MD
    • District of Columbia
      • Washington D.C., District of Columbia, Stati Uniti, 20010
        • Reclutamento
        • Washington Hospital Center
        • Investigatore principale:
          • Sheikh Farooq, MD
        • Contatto:
    • Florida
      • Gainesville, Florida, Stati Uniti, 32610
        • Reclutamento
        • Shands at the University of Florida
        • Investigatore principale:
          • Mustafa Ahmed, MD
        • Contatto:
      • Weston, Florida, Stati Uniti, 33331
        • Reclutamento
        • Cleveland Clinic Florida
        • Contatto:
          • Maria Mejia-Gomez
          • Numero di telefono: 954-659-5888
          • Email: mejiagm@ccf.org
        • Investigatore principale:
          • Mauricio Velez, MD
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30309
        • Reclutamento
        • Piedmont Heart Institute
        • Investigatore principale:
          • Catherine Marti, MD
        • Contatto:
      • Augusta, Georgia, Stati Uniti, 30901
        • Reclutamento
        • Piedmont Augusta Hospital
        • Investigatore principale:
          • Darshak Karia, MD
        • Contatto:
      • Marietta, Georgia, Stati Uniti, 30060
        • Reclutamento
        • WellStar Kennestone Hospital
        • Investigatore principale:
          • Abdul Bikak, MD
        • Contatto:
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60637
        • Reclutamento
        • University of Chicago
        • Contatto:
        • Investigatore principale:
          • Nikhil Narang, MD
      • Oakbrook Terrace, Illinois, Stati Uniti, 60181
        • Reclutamento
        • Advocate Health & Hospitals Corporation
        • Contatto:
        • Investigatore principale:
          • Vinh Chau, MD
    • Indiana
      • Indianapolis, Indiana, Stati Uniti, 46240
        • Reclutamento
        • St. Vincent Hospital
        • Investigatore principale:
          • Ashwin Ravichandran, MD
        • Contatto:
    • Iowa
      • Iowa City, Iowa, Stati Uniti, 52242
        • Reclutamento
        • University of Iowa Hospitals & Clinics
        • Contatto:
        • Investigatore principale:
          • Anthony Panos, MD
    • Kansas
      • Kansas City, Kansas, Stati Uniti, 66160
        • Reclutamento
        • Kansas University Medical Center
        • Contatto:
        • Investigatore principale:
          • Zubair Shah, MD
    • Kentucky
      • Lexington, Kentucky, Stati Uniti, 40536
        • Terminato
        • University of Kentucky
      • Louisville, Kentucky, Stati Uniti, 40202
        • Reclutamento
        • Norton Hospital
        • Contatto:
        • Investigatore principale:
          • Alkhalil Bassel, MD
    • Maine
      • Portland, Maine, Stati Uniti, 04102
        • Reclutamento
        • Maine Medical Center
        • Contatto:
        • Investigatore principale:
          • Peter Kennel, MD
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02114
        • Reclutamento
        • Massachusetts General Hospital
        • Contatto:
        • Investigatore principale:
          • Erin Coglianese, MD
    • Michigan
      • Detroit, Michigan, Stati Uniti, 48202
        • Reclutamento
        • Henry Ford Hospital
        • Contatto:
        • Investigatore principale:
          • Lindsey Aurora, MD
      • Grand Rapids, Michigan, Stati Uniti, 49503
        • Reclutamento
        • Spectrum Health Butterworth Hospital
        • Contatto:
        • Investigatore principale:
          • Matthew Gonzalez, MD
    • Minnesota
      • Minneapolis, Minnesota, Stati Uniti, 55407
        • Reclutamento
        • Minneapolis Heart Institute
        • Investigatore principale:
          • Mosi Bennett, MD
        • Contatto:
      • Rochester, Minnesota, Stati Uniti, 55905
        • Reclutamento
        • Mayo Clinic
        • Contatto:
        • Investigatore principale:
          • Andrew Rosenbaum, MD
    • Missouri
      • Kansas City, Missouri, Stati Uniti, 64111
        • Reclutamento
        • St. Luke's Hospital
        • Investigatore principale:
          • Timothy Fendler, MD
        • Contatto:
    • Nebraska
      • Omaha, Nebraska, Stati Uniti, 68198
        • Reclutamento
        • University of Nebraska Medical Center
        • Contatto:
        • Investigatore principale:
          • Adam Burdorf, DO
    • New Jersey
      • Hackensack, New Jersey, Stati Uniti, 07601
        • Reclutamento
        • Hackensack University Medical Center
        • Investigatore principale:
          • Kanika Mody, MD
        • Contatto:
      • Newark, New Jersey, Stati Uniti, 07112
        • Reclutamento
        • Newark Beth Israel Medical Center
        • Investigatore principale:
          • Igor Gosev, MD
        • Contatto:
    • New Mexico
      • Albuquerque, New Mexico, Stati Uniti, 87102
        • Reclutamento
        • New Mexico Heart Institute
        • Contatto:
        • Investigatore principale:
          • Dana Booth, MD
    • New York
      • Manhasset, New York, Stati Uniti, 11030
        • Reclutamento
        • North Shore University Hospital
        • Contatto:
        • Investigatore principale:
          • Maria Avila, MD
      • New York, New York, Stati Uniti, 10032
        • Reclutamento
        • New York-Presbyterian/Columbia University Medical Center
        • Contatto:
        • Investigatore principale:
          • Dor Lotan, MD
      • Rochester, New York, Stati Uniti, 14642
        • Reclutamento
        • University of Rochester Medical Center
        • Contatto:
        • Investigatore principale:
          • Leway Chen, MD
      • The Bronx, New York, Stati Uniti, 10467
        • Reclutamento
        • Montefiore Medical Center - Moses Campus
        • Investigatore principale:
          • Yogita Rochlani, MD
        • Contatto:
    • North Carolina
      • Chapel Hill, North Carolina, Stati Uniti, 27599
        • Reclutamento
        • University of North Carolina at Chapel Hill
        • Contatto:
        • Investigatore principale:
          • William Mostertz, MD
      • Charlotte, North Carolina, Stati Uniti, 28203
        • Reclutamento
        • Carolinas Medical Center
        • Contatto:
        • Investigatore principale:
          • Joseph Mishkin, MD
    • Ohio
      • Cincinnati, Ohio, Stati Uniti, 45219
      • Cleveland, Ohio, Stati Uniti, 44195
        • Reclutamento
        • The Cleveland Clinic Foundation
        • Contatto:
          • Barbara Gus
          • Numero di telefono: 216-445-6552
          • Email: gusb@ccf.org
        • Investigatore principale:
          • Michael Tong, MD
    • Oklahoma
      • Oklahoma City, Oklahoma, Stati Uniti, 73112
        • Reclutamento
        • Integris Baptist Medical Center
        • Contatto:
        • Investigatore principale:
          • Luke Cunningham, MD
      • Tulsa, Oklahoma, Stati Uniti, 74104
        • Reclutamento
        • Oklahoma Heart Institute at Utica
        • Contatto:
        • Investigatore principale:
          • Luis David Meggo Quiroz, MD
      • Tulsa, Oklahoma, Stati Uniti, 74136
        • Reclutamento
        • Saint Francis Hospital
        • Investigatore principale:
          • Douglas Ensley, MD
        • Contatto:
    • Oregon
      • Portland, Oregon, Stati Uniti, 97239
        • Reclutamento
        • Oregon Health & Science University
        • Investigatore principale:
          • Johannes Steiner, MD
        • Contatto:
    • Pennsylvania
      • Abington, Pennsylvania, Stati Uniti, 19001
        • Reclutamento
        • Abington Memorial Hospital
        • Contatto:
        • Investigatore principale:
          • Alexander Shpilman, MD
      • Hershey, Pennsylvania, Stati Uniti, 17033
        • Reclutamento
        • Penn State Milton S. Hershey Medical Center
        • Investigatore principale:
          • John Boehmer, MD
        • Contatto:
      • Philadelphia, Pennsylvania, Stati Uniti, 19104
        • Reclutamento
        • University of Pennsylvania
        • Contatto:
        • Investigatore principale:
          • Himabindu Vidula, MD
      • Philadelphia, Pennsylvania, Stati Uniti, 15213
        • Reclutamento
        • University of Pittsburgh Medical Center (UPMC)
        • Investigatore principale:
          • Gavin Hickey, MD
        • Contatto:
      • Pittsburgh, Pennsylvania, Stati Uniti, 15212
        • Reclutamento
        • Allegheny General Hospital
        • Investigatore principale:
          • Matthew Lander, MD
        • Contatto:
    • South Carolina
      • Charleston, South Carolina, Stati Uniti, 29425
        • Reclutamento
        • Medical University of South Carolina
        • Investigatore principale:
          • Arman Kilic, MD
        • Contatto:
      • Columbia, South Carolina, Stati Uniti, 29203
    • Tennessee
      • Memphis, Tennessee, Stati Uniti, 38120
        • Reclutamento
        • The Stern Cardiovascular Foundation
        • Contatto:
        • Investigatore principale:
          • Todd Edwards, MD
    • Texas
      • Austin, Texas, Stati Uniti, 78705
        • Reclutamento
        • Ascension Texas Cardiovascular
        • Contatto:
        • Investigatore principale:
          • Raymond Bietry, MD
      • Dallas, Texas, Stati Uniti, 75246
        • Reclutamento
        • Baylor University Hospital
        • Contatto:
        • Investigatore principale:
          • Cesar Guerrero-Miranda, MD
      • Houston, Texas, Stati Uniti, 77030
        • Reclutamento
        • Houston Methodist
        • Contatto:
        • Investigatore principale:
          • Cindy Martin, MD
      • Houston, Texas, Stati Uniti, 77030
        • Reclutamento
        • CHI St. Luke's Health Baylor College of Medicine Medical Center
        • Investigatore principale:
          • Ajith Nair, MD
        • Contatto:
      • Houston, Texas, Stati Uniti, 77030
        • Reclutamento
        • UTHealth Memorial Hermann
        • Contatto:
        • Investigatore principale:
          • Nathan Sriram, MD
      • Plano, Texas, Stati Uniti, 75093
        • Reclutamento
        • The Heart Hospital Baylor Plano
        • Contatto:
        • Investigatore principale:
          • Aasim Afzal, MD
      • Temple, Texas, Stati Uniti, 76508
        • Reclutamento
        • Scott & White Memorial Hospital
        • Contatto:
        • Investigatore principale:
          • Yevgeniy Khariton, MD
    • Utah
      • Salt Lake City, Utah, Stati Uniti, 84132
        • Reclutamento
        • University of Utah Hospital
        • Investigatore principale:
          • Craig Selzman, MD
        • Contatto:
    • Virginia
      • Charlottesville, Virginia, Stati Uniti, 22908
        • Reclutamento
        • University of Virginia Medical Center
        • Contatto:
        • Investigatore principale:
          • Mirnela Byku, MD
      • Richmond, Virginia, Stati Uniti, 23219
        • Reclutamento
        • Virginia Commonwealth University
        • Investigatore principale:
          • Keyur Shah, MD
        • Contatto:
    • Wisconsin
      • Milwaukee, Wisconsin, Stati Uniti, 53215
        • Reclutamento
        • Aurora Medical Group
        • Investigatore principale:
          • Nasir Sulemanjee, MD
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Subject has provided written informed consent by signing the study Informed Consent Form (ICF) prior to any clinical investigation-related procedure
  2. LVEF ≤30% and Cardiac Index ≤ 2.5 L/min/m²
  3. Limited functional status as demonstrated by 6MWT ≤ 350 m due to HF related reasons OR peak VO2 ≤ 14 mL/kg/min (or <50% of predicted peak VO2 value)
  4. NYHA Class IIIB or NYHA Class IV
  5. Subject has ≥ 1 Heart Failure Hospitalization in the last 12 months
  6. Subject is already implanted with a CardioMEMS PA Sensor OR willing to undergo a CardioMEMS PA Sensor implant
  7. Subject is willing and able to be implanted with the HM3 LVAS if randomized to HM3 Group

Randomization Criteria:

  1. Subject has been implanted with a CardioMEMS PA Sensor for at least 90 days.
  2. Subject is receiving guideline directed medical therapy with optimal doses (or documented medication contraindication or intolerance) of betablockers, Angiotensin-Converting-Enzyme-inhibitors or Angiotensin II Receptor Blockers or angiotensin receptor neprilysin inhibitor (if eligible), Mineralocorticoid Receptor Antagonists, Sodium-Glucose co-Transporter-2 (SGLT2) inhibitors, and diuretics for at least 30 of the last 90 days.
  3. mean PAP ≥ 30 mmHg.
  4. The subject will not be randomized if they have any other factor that represents inordinate risk for either continued GDMT or LVAD implant.

Single Arm Registry Criteria:

  1. Subject has received a CardioMEMS PA Sensor implant following enrollment in the trial.
  2. Subject is receiving guideline directed medical therapy with optimal doses (or documented medication contraindication or intolerance) of betablockers, Angiotensin-Converting-Enzyme-inhibitors or Angiotensin II Receptor Blockers or angiotensin receptor neprilysin inhibitor (if eligible), Mineralocorticoid Receptor Antagonists, Sodium-Glucose co-Transporter-2 (SGLT2) inhibitors, and diuretics for at least 30 of the last 90 days.
  3. mean PAP <30 mmHg

Exclusion Criteria:

  1. Subject is < 18 years of age at the time of informed consent.

  2. Dependent on IV inotrope in the last 30 days.

  3. Contra-indications to HM3 LVAS or CardioMEMS HF system.

  4. Etiology of HF due to or associated with uncorrected thyroid disease, obstructive cardiomyopathy, pericardial disease, amyloidosis, or restrictive cardiomyopathy.

  5. Technical obstacles to LVAD or CardioMEMS implantation which pose an inordinately high surgical risk, in the judgment of the implanter.

  6. Existence of ongoing MCS.

  7. Presence of mechanical aortic valve that will not be either converted to a bioprosthesis or oversewn at the time of LVAD implant.

  8. History of any solid organ transplant.

  9. Psychiatric disease/disorder, irreversible cognitive dysfunction or psychosocial issues that are likely to impair compliance with the study protocol and LVAS management.

  10. Presence of an active, uncontrolled infection.

  11. Complex congenital heart disease.

  12. Currently Pregnant or capable of becoming Pregnant and Unwilling to Use Contraception with LVAD.

  13. History of pulmonary embolism within 30 days prior to enrollment or history of recurrent (>1 episode) pulmonary embolism and/or deep vein thrombosis.

  14. Planned VAD or Bi-VAD support prior to enrollment.

  15. Presence of any one of the following risk factors for or indications of severe end organ dysfunction or failure:

    1. An INR ≥ 2.0 not due to anticoagulation therapy
    2. An eGFR < 30 mL/min/1.73 m2 and nonresponsive to diuretic therapy or receiving chronic dialysis.
    3. Biopsy proven liver cirrhosis.
    4. Need for chronic renal replacement therapy.
    5. History of severe chronic obstructive pulmonary disease (COPD) defined by Forced Expiratory Volume FEV1 < 30% predicted.
    6. History of cerebrovascular disease with significant (> 80%) uncorrected internal carotid stenosis.
    7. Significant peripheral vascular disease (PVD) accompanied by ischemic rest pain or extremity ulceration.
  16. Any condition other than HF that could limit survival to less than 24 months.

  17. Participation in any other clinical investigation with an active treatment arm that is likely to confound study results or affect the study outcome.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Randomized Arm - HM3 Group

Patients with elevated mean PAP (mean PAP ≥ 30 mmHg) and randomized to the HM3 group will receive the device within 14 days of randomization.

The CardioMEMS™ HF System is comprised of a lead-less and battery-less pressure sensor which remotely transmits pulmonary artery pressure measurements.

Altri nomi:
  • CardioMEMS
  • Sensore PA CardioMEMS

The HeartMate 3 LVAS is a mechanical circulatory support pump with Full MagLev Technology that assumes some or all of the workload of the left ventricle. The HeartMate 3 LVAS is used in advanced heart failure patients needing short or long-term mechanical circulatory support.

Altri nomi:
  • HM3

Optimal doses of medical therapy per established heart failure guidelines which includes the following stable combination of Beta Blockers, ACE-inhibitors or ARB or ARNi, MRA and SGLT2 inhibitors.

Altri nomi:
  • GDMT
Sperimentale: Randomized Arm - Control Group

Patients with elevated mean PAP (mean PAP ≥ 30 mmHg) and randomized to the control group will continue their medical therapy per established heart failure guidelines.

The CardioMEMS™ HF System is comprised of a lead-less and battery-less pressure sensor which remotely transmits pulmonary artery pressure measurements.

Altri nomi:
  • CardioMEMS
  • Sensore PA CardioMEMS

Optimal doses of medical therapy per established heart failure guidelines which includes the following stable combination of Beta Blockers, ACE-inhibitors or ARB or ARNi, MRA and SGLT2 inhibitors.

Altri nomi:
  • GDMT
Sperimentale: Single Arm Registry

Patients who do not meet the mean PAP threshold (mean PAP <30 mmHg) and are enrolled in the single arm will continue their medical therapy per established heart failure guidelines.

The CardioMEMS™ HF System is comprised of a lead-less and battery-less pressure sensor which remotely transmits pulmonary artery pressure measurements.

Altri nomi:
  • CardioMEMS
  • Sensore PA CardioMEMS

Optimal doses of medical therapy per established heart failure guidelines which includes the following stable combination of Beta Blockers, ACE-inhibitors or ARB or ARNi, MRA and SGLT2 inhibitors.

Altri nomi:
  • GDMT

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Survival at 2 years free of disabling stroke, reoperation to replace the device, or worsening HF requiring listing for urgent heart transplantation or mechanical circulatory support, enrollment into hospice, or dependence on IV inotropes
Lasso di tempo: 2 years

The powered primary endpoint will be analyzed at 2 years following the Com-Nougue method and will be compared between the HM3 Group (HM3 LVAD) and the Control Group (GDMT) within the Intention-to-treat (ITT) population.

2 years

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Rate of Safety Outcomes at 1-year
Lasso di tempo: 1 year

The powered secondary endpoint of Rate of Safety Outcomes at 1-year will be evaluated within the Intention-to-treat (ITT) population against a pre-specified performance goal.

Components consist of the following:

  1. Heart failure hospitalization

  2. Major Adverse Event (MAE) including:

    • Stroke
    • Non-surgical bleeding (>14 days post implant) requiring hospitalization
    • Renal failure requiring hospitalization
    • Driveline infection requiring hospitalization
1 year
Survival at 2 years
Lasso di tempo: 2 years

The powered secondary endpoint of survival at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population.

2 years
Quality of life score assessed with the Kansas City Cardiomyopathy Questionnaire
Lasso di tempo: 2 years

The secondary endpoint of Quality-of-life score at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of Quality of life at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately.

The KCCQ scores are represented on a 0-to-100-point scale, where lower scores represent more severe symptoms and/or limitations and scores of 100 indicate no symptoms, no limitations, and excellent quality of life. Improvement of KCCQ by at least 10 points is considered clinically significant.

2 years
Six-minute walk distance
Lasso di tempo: 2 years

The secondary endpoint of six-minute walk distance at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of six-minute walk distance at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately.

2 years
Hospitalizations for HF and/or Urgent HF Visit
Lasso di tempo: 2 years

The secondary endpoint of Hospitalizations for HF and/or Urgent HF Visit at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of Hospitalizations for HF and/or Urgent HF Visit at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately.

2 years
Days alive and outside of the hospital
Lasso di tempo: 2 years

The secondary endpoint of days alive and outside of the hospital at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of days alive and outside of the hospital at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately.

2 years
All-cause hospitalizations
Lasso di tempo: 2 years

The secondary endpoint of all-cause hospitalizations at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of all-cause hospitalizations at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately.

2 years
All adverse events (including all strokes) regardless of severity
Lasso di tempo: 2 years

The secondary endpoint of all adverse events (including all strokes) regardless of severity at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of all adverse events (including all strokes) regardless of severity at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately.

2 years

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Finkelstein-Schoenfeld Win Ratio
Lasso di tempo: 5 years

The Finkelstein-Schoenfeld Win Ratio will be explored at 5 years as an additional analysis with the following hierarchy:

  1. Survival
  2. Days alive outside of the hospital
  3. Quality of Life assessed with the KCCQ (considered a tie if within 10 points)
  4. Functional Capacity (Six-minute walk distance)

The Finkelstein-Schoenfeld Win Ratio will be analyzed between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the Finkelstein-Schoenfeld Win Ratio will be descriptively analyzed between the Single Arm and both the HM3 Group and Control Group of the Randomized Arm separately.

5 years
Survival free of urgent LVAD or transplant
Lasso di tempo: 5 years

This additional descriptive analysis at 5-years will be performed to evaluate the proportion of patients who are alive and free of device replacement or transplant in the HM3 Group compared to the Single Arm Registry (de novo implant or transplant)

5 years

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Direttore dello studio: Kelly O'Connell, PhD, Abbott

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

13 dicembre 2024

Completamento primario (Stimato)

1 settembre 2029

Completamento dello studio (Stimato)

1 settembre 2032

Date di iscrizione allo studio

Primo inviato

24 luglio 2024

Primo inviato che soddisfa i criteri di controllo qualità

24 luglio 2024

Primo Inserito (Effettivo)

29 luglio 2024

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

5 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

3 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

Sì

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi